



Clearside Biomedical to Present at the UBS Global Healthcare Conference

May 15, 2019

ALPHARETTA, Ga., May 15, 2019 (GLOBE NEWSWIRE) --

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that Brion Raymond, Chief Commercial Officer, will present a company overview at the UBS Global Healthcare Conference in New York, NY on Wednesday, May 22, 2019 at 11:00 a.m. ET.

A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: [Events and Presentations](#). An archive of the webcast will be available for three months.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases. Clearside's proprietary suprachoroidal treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs. The Company's unique Suprachoroidal Space (SCS) Injection Platform for eye disease treatments is an inherently flexible and non-surgical procedure, intended to work with established medications, new formulations of medicines, as well as future therapeutic innovations such as gene therapy. Clearside is headquartered in Alpharetta, GA. For more information, please visit <http://www.clearsidebio.com>.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.



Source: Clearside Biomedical, Inc.